SCHEMBL364615

SCHEMBL364615

COc1cc(COc2ccc(C(=O)NS(C)(=O)=O)cc2)ccc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
SCN9A Q15858 6/20 0.48
SCN5A Q14524 2/20 0.48
ALKBH1 Q13686 1/20 0.48
TAS2R14 Q9NYV8 1/20 0.47
PTGER4 P35408 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.45
BCL2L1 Q07817 1/20 0.44
MCL1 Q07820 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL364950 0.88 MAOB (0.66) MAOAMAOBALDH1A1MAPTHTT
SCHEMBL16239768 0.83 ALDH1A1 (0.70) ALDH1A1MAPTHTTSCN9APTGER4
SCHEMBL365645 0.83 ALDH1A1 (0.70) ALDH1A1MAPTHTTSCN9APTGER4
SCHEMBL365348 0.83 SCN9A (0.56) MAOAMAOBALDH1A1MAPTHTT
SCHEMBL366812 0.82 MAOB (0.63) MAOBALDH1A1MAPTHTTSCN9A
SCHEMBL14889855 0.81 SCN9A (0.53) MAOBALDH1A1MAPTHTTSCN9A
SCHEMBL14890621 0.81 GSK3B (0.55) MAOBALDH1A1MAPTHTTSCN9A
SCHEMBL366713 0.80 RAB9A (0.57) MAOBALDH1A1MAPTHTTPTGER4
SCHEMBL14890368 0.80 SCN9A (0.54) MAOBALDH1A1SCN9ASCN5APTGER4
SCHEMBL365210 0.79 MAOA (0.63) MAOAMAOBALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A MAOA 3705/4885MAOB 3660/4885ALDH1A1 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.